

in association with



society of hematologic oncology

promoted by



With the Patronages of



1 SOHO ITALY

Clinical And Biological School of Multiple Myeloma

Virtual Event 15 16 17 Dec. 2020
www.sohoitaly.it



JOIN US!



@sohoitaly
#sohoitalyMM20

Registration



Organizing secretariat



www.proeventi.it
info@proeventi.it

20 CME (ECM) HEMATOLOGISTS, ONCOLOGISTS, PATHOLOGIST, BIOLOGISTS

1 SOHO ITALY

Clinical And Biological
School of **Multiple Myeloma**

15 16 17 Dec. 2020

Virtual Event

Presidents:

Cerchione C, Martinelli G, Lee HC, Mateos MV, Anderson KC

Scientific Board:

Cerchione C, Martinelli G, Lee HC, Mateos MV, Anderson KC

Scientific Secretariat:

Cerchione C, Martinelli G, Musuraca G, Ronconi S, Ceccolini M

Big Faculty:

**Cerchione C, Martinelli G, Lee HC, Mateos MV, Anderson KC,
Antonioli E, Boccadoro M, Bolli N, Bosi A, Cavo M, Derudas D, Di Raimondo F,
Gay F, Gentile M, Lanza F, Larocca A, Martino M, Montefusco V, Olivieri A,
Petrucci MT, Romano A, Terragna C, Tosi P, Vacca A, Zamagni E**

Day 0

15 Dec 2020

- 19.00 - 19.30 Lecture: How I manage Multiple Myeloma in Europe in 2020 – [C. Cerchione](#)
- 19.30 - 20.00 Lecture: How I manage Smoldering Multiple Myeloma in 2020 – [M.V. Mateos](#)
- 20.00 - 20.30 Lecture: How I manage relapsed/refractory Multiple Myeloma at MD Anderson Cancer Center – [H. Lee](#)
- 20.30 - 21.00 Lecture: Future of Multiple Myeloma – [K.C. Anderson](#)

Day 1

16 Dec 2020

Frontal Session

- 08.30-08.50 Opening and introduction to the project:
[C. Cerchione](#) – [G. Martinelli](#)
- Biology and MRD in Multiple Myeloma** [N. Bolli](#) – [C. Terragna](#) – [G. Martinelli](#)
- 08.50 – 09.10 Molecular pathogenesis of multiple myeloma – [N. Bolli](#)
- 09.10 – 09.30 Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma – [C. Terragna](#)
- 09.30 - 09.50 Exploring microenvironment – from biology to therapy – [A. Romano](#)
- 09.50 – 10.10 Importance of imaging for MRD evaluations – [E. Zamagni](#)

10.10 – 10.30 Future perspectives in MRD in Multiple Myeloma: where are we going? – [G. Martinelli](#)

10.30 – 10.50 break

Clinical Session 1 – C. Cerchione – K.C. Anderson – M.V. Mateos

10.50 – 11.10 Present and future of management of frontline Multiple Myeloma – [M.V. Mateos](#)

11.10 – 11.30 Present and future of management of relapsed/refractory Multiple Myeloma – [C. Cerchione](#)

11.30 – 11.50 Major differences between Europe and USA in the management of Multiple Myeloma – [K.C. Anderson](#)

11.50 – 12.10 Antibody-Drug Conjugates (ADCs) and Bispecific T-cell Engagers (TCEs) in Multiple Myeloma: How are they changing the current panorama – [H. Lee](#)

12.10 – 12.20 Discussion

Clinical Session 2 – A. Bosi – A. Olivieri – V. Montefusco Frontline setting

12.20 – 12.40 Transplant-eligible patients: old versus new – [V. Montefusco](#)

12.40 – 13.00 Role of consolidation in MM in novel agents era – [E. Antonioli](#)

13.00 – 13.20 Role of autologous stem cell transplantation in MM in novel agents era – [M.T. Petrucci](#)

13.20 – 13.40 Role of allogenic stem cell transplantation in MM in novel agents era – [A. Olivieri](#)

13.40 – 14.00 Established and new options for maintenance therapy – [M. Cavo](#)

14.00 – 14.20 Discussion

14.20 - 15.30 **Symposium**

Clinical Session 3 – F. Lanza, P. Tosi, D. Derudas
Allo and auto transplant: when and why

Transplant-inelegible patients: old and new options for elderly fit patients – [P. Tosi](#)

15.50 – 16.10 Transplant-inelegible patients: old and new options for elderly – unfit/frail patients – [A. Larocca](#)

16.10 – 16.30 Extramedullary disease and plasma cell leukemia
[D. Derudas](#)

Clinical Session 4 – M. Martino, F. Di Raimondo, A. Vacca
Near future of Multiple Myeloma

16.30 – 16.50 Balancing efficacy and tolerability in novel agents-based treatments – [M. Gentile](#)

16.50 – 17.10 How is real world changing – [M. Boccadoro](#)

17.10 – 17.30 CAR-T: lights and shadows in Italy – [M. Martino](#)

17.30 – 17.50 New Drugs on the Horizon – [F. Di Raimondo](#)

17.50 – 18.10 Endothelial cells and dendritic cells as immunosuppressive agents in patients with Multiple Myeloma – [A. Vacca](#)

18.10 – 18.30 Discussion – Questions and Answers

Young session

Selected oral presentations with project presentations in different categories

Chairs Big Faculty:

Cerchione C, Martinelli G, Lee HC, Mateos MV, Anderson KC, Antonioli E, Boccadoro M, Bolli N, Bosi A, Cavo M, Derudas D, Di Raimondo F, Gay F, Gentile M, Lanza F, Larocca A, Martino M, Montefusco V, Olivieri A, Petrucci MT, Romano A, Terragna C, Tosi P, Vacca A, Zamagni E

15 min presentation + 15 min discussion)

1. 08.30-09.00 Biology of Multiple Myeloma
2. 09.00-09.30 MRD tools in Multiple Myeloma
3. 09.30-10.00 Smoldering Multiple Myeloma: present and near future
4. 10.00 - 10.30 Transplant-eligible patients
- 10.30 - 11.00 Questions and answers and discussion for future papers
- 11.00 - 11.15 break

5. 11.15 - 11.45 Maintenance therapy
6. 11.45 - 12.15 Transplant-inelegible patients - elderly fit patients
7. 12.15 - 12.45 Transplant-inelegible patients elderly - unfit/frail patients
8. 12.45 - 13.15 Extramedullary disease and plasma cell leukemia
- 13.15 - 13.45 Questions and answers and discussion for future papers
- 13.45 - 14.45 **Symposium**
Introducing anti-CD38 in daily practice of Multiple Myeloma - C. Cerchione
- 14.45 - 16.00 **Poster walk**
9. 16.00 - 16.30 Relapsed/refractory Multiple Myeloma 1
10. 16.30 - 17.00 Relapsed/refractory Multiple Myeloma 2
11. 17.00 - 17.30 Relapsed/refractory Multiple Myeloma 3
12. 17.30 - 18.00 Novel drug targets and therapies
- 18.00 - 18.30 Present and future of European Myeloma Network (EMN) Clinical Trials - F. Gay

(After presentations, all projects will be started to be defined, with their teams, objectives and timepoints)

- 18.30 - 19.00 Questions and answers and discussion for present and future projects
- Conclusions and next steps
C. Cerchione, G. Martinelli

in associaton with



promoted by



supported by an unrestricted educational grant form



Follow us!

The use of social media is extremely important to build a stronger relationship and to improve the interaction between speakers and attendees, so do not forget to use them!

Our official hashtag is #SOHOITALYMM20

You can use it on Facebook, Twitter, Instagram and LinkedIn

Put your like on our social pages and follow us!

You can tweet with:

@sohoitaly
@sohoItalyMM20
@SocietyofHemOnc
@IRSTufficiale
@MDAndersonNews
@pro_eventi
@GMartinelli2
@DottorClaudio
@mvmateos
@MaxMartinoRC

Follow us!



#SOHOITALYMM20

in association with



society of hematologic oncology

Promoted by



SERVIZIO SANITARIO REGIONALE
EMILIA-ROMAGNA

Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
Istituto di Ricovero e Cura a Carattere Scientifico

ISTITUTO
ROMAGNOLO
PER LO STUDIO
DEI TUMORI
DINO AMADORI

1 SOHO ITALY

Clinical And Biological
School of Multiple Myeloma